


# Companies In The Interleukin Inhibitors Industry Are Focusing On Biosimilar Development

*The Business Research Company's Interleukin Inhibitors Global Market Report 2021: COVID-19 Growth And Change To 2030*

LONDON, GREATER LONDON , UK, April 6, 2021 /EINPresswire.com/ -- Our reports have been revised for market size, forecasts, and strategies to take on 2021 after the COVID-19 impact: <https://www.thebusinessresearchcompany.com/global-market-reports>



Patent expiry of biologic drugs is opening opportunities for biosimilar drugs, which are a cheap alternative and thus among [interleukin inhibitors market](#) trends. Major companies in the interleukins sector are focusing on developing biosimilars for interleukin inhibitors. For instance, biosimilars for IL inhibitors such as canakinumab (Ilaris), ustekinumab (Stelara), tocilizumab (Actemra), and secukinumab (Cosentyx) among others are in development by Mabpharm, NeuClone Pharmaceuticals Ltd, Gedeon Richter, and Bio-Thera Solutions, respectively. Despite the clinical benefits associated with the use of biologics in psoriasis and other autoimmune diseases, many patients are not treated with biologic therapy, and access to treatment may be limited for several reasons including higher treatment costs. This factor coupled with rapid advances in biotechnology and analytical sciences, which ensure comparability of biosimilars to biologic drugs, drive the trend for biosimilars.

The interleukins inhibitors market covered in this report is segmented by type into IL-17, IL-23, IL-1, IL-5, IL-6, others. The interleukin inhibitors market is also segmented by application into psoriasis, psoriatic arthritis, rheumatoid arthritis, asthma, inflammatory bowel disease, others and by application into hospital pharmacies, retail pharmacies, online pharmacies.

Read More On The Global Interleukin Inhibitors Market Report:

<https://www.thebusinessresearchcompany.com/report/interleukin-inhibitors-global-market-report-2020-30-covid-19-growth-and-change>

The global interleukin inhibitors market size is expected to grow from \$17.73 billion in 2020 to \$19.88 billion in 2021 at a compound annual growth rate (CAGR) of 12.1%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The interleukin inhibitors market is expected to reach \$32 billion in 2025 at a CAGR of 13%. The countries with interleukin inhibitors market shares are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

Major players in the interleukin inhibitors market are Sanofi, GlaxoSmithKline, Novartis, Johnson & Johnson, Roche, Eli Lilly, AstraZeneca, Teva Pharmaceutical, and Regeneron Pharmaceuticals.

[Interleukin Inhibitors Global Market Report 2021: COVID-19 Growth And Change To 2030](#) is one of a series of new reports from The Business Research Company that provides interleukin inhibitors market overview, forecast interleukin inhibitors market size and growth for the whole market, interleukin inhibitors market segments, and geographies, interleukin inhibitors market trends, interleukin inhibitors market drivers, restraints, leading competitors' revenues, profiles, and market shares.

Request For A Sample Of The Global Interleukin Inhibitors Market Report:

<https://www.thebusinessresearchcompany.com/sample.aspx?id=3469&type=smp>

Here Is A List Of Similar Reports By The Business Research Company:

Oral Biologics And Biosimilars Market - By Therapeutic Mechanism (Tumor Necrosis Factor-Alpha Inhibitors, Lymphocyte Modulators, Interleukin Inhibitors, GPCR (insulin, growth hormone, parathyroid hormone) Modulators, Immunostimulants, Others), By Disease (Diabetes, Arthritis & Chron `s Disease, Cancer, Infectious Diseases, Other Autoimmune Diseases, Others Diseases), By Molecule Type (Vaccines, Proteins & Peptides, Monoclonal Antibodies, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), And By Region, Opportunities And Strategies - Global Forecast To 2030

<https://www.thebusinessresearchcompany.com/report/oral-biologics-and-biosimilars-market>

Dermatitis Global Market Report 2021: COVID 19 Impact and Recovery to 2030

<https://www.thebusinessresearchcompany.com/report/dermatitis-drugs-global-market-report>

Psoriasis Global Market Report 2021: COVID 19 Impact and Recovery to 2030

<https://www.thebusinessresearchcompany.com/report/psoriasis-drugs-global-market-report>

Interested to know more about [The Business Research Company?](#)

Read more about us at <https://www.thebusinessresearchcompany.com/about-the-business-research-company.aspx>

The Business Research Company is a market research and intelligence firm that excels in company, market, and consumer research. It has over 200 research professionals at its offices in India, the UK and the US, as well a network of trained researchers globally. It has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services and technology. TBRC excels in company, market, and consumer research.

Call us now for personal assistance with your purchase:

Europe: +44 207 1930 708

Asia: +91 88972 63534

Americas: +1 315 623 0293

Oliver Guirdham

The Business Research Company

+44 20 7193 0708

info@tbrc.info

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/538101040>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2021 IPD Group, Inc. All Right Reserved.